Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

NCT02194777 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2014-07-23

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single inhalative administration of increasing doses in healthy male and female volunteers

Conditions

Healthy

Interventions

DRUG: BIBN 4096 BS - in single rising doses
DRUG: Placebo

Sponsors & Collaborators

Boehringer Ingelheim
lead INDUSTRY

Study Design

Allocation: RANDOMIZED
Purpose: TREATMENT
Masking: DOUBLE
Model: SINGLE_GROUP

Eligibility

Min Age: 21 Years
Max Age: 50 Years
Sex: ALL
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2001-06-30
Primary Completion: 2001-08-31

More Related Trials

Entities

Drugs

Placebo

Companies

Boehringer Ingelheim

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Related Clinical Trials

Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers

Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

More Related Trials

Entities